Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bizengri

(bi-ZEN-gree)

A drug used to treat adults with non-small cell lung cancer and a type of pancreatic cancer called pancreatic adenocarcinoma. It is used in patients whose cancer has an NRG1 gene fusion, and has spread or cannot be removed by surgery after systemic therapy. It is also being studied in the treatment of other types of cancer. Bizengri binds to two proteins called HER2 and HER3, which are found on some cancer cells. This may help keep cancer cells from growing and may help the immune system kill cancer cells. Bizengri is a type of monoclonal antibody. Also called zenocutuzumab.

Bizengri

Search NCI's Dictionary of Cancer Terms